Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
Zent CS, Taylor RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, Call TG, Bowen DA, Conte MJ, Frederick LA, Link BK, Blackwell SE, Veeramani S, Baig NA, Viswanatha DS, Weiner GJ, Witzig TE. Zent CS, et al. Among authors: conte mj. Am J Hematol. 2014 Jul;89(7):757-65. doi: 10.1002/ajh.23737. Epub 2014 Apr 26. Am J Hematol. 2014. PMID: 24723493 Free PMC article. Clinical Trial.
Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.
Zent CS, Call TG, Bowen DA, Conte MJ, LaPlant BR, Witzig TE, Ansell SM, Weiner GJ. Zent CS, et al. Among authors: conte mj. Leuk Lymphoma. 2015;56(8):2373-8. doi: 10.3109/10428194.2015.1016932. Epub 2015 Mar 17. Leuk Lymphoma. 2015. PMID: 25676035 Free PMC article. Clinical Trial.
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM. Ding W, et al. Among authors: conte mj. Blood. 2017 Jun 29;129(26):3419-3427. doi: 10.1182/blood-2017-02-765685. Epub 2017 Apr 19. Blood. 2017. PMID: 28424162 Free PMC article. Clinical Trial.
Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings.
Hampel PJ, Chaffee KG, King RL, Simonetto D, Larson MC, Achenbach S, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Bowen DA, Conte MJ, Schwager SM, Hanson CA, Slager SL, Kay NE, Shanafelt TD, Parikh SA. Hampel PJ, et al. Among authors: conte mj. Am J Hematol. 2017 Dec;92(12):1362-1369. doi: 10.1002/ajh.24915. Epub 2017 Oct 19. Am J Hematol. 2017. PMID: 28940587 Free PMC article.
Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.
Larsen JT, Shanafelt TD, Leis JF, LaPlant B, Call T, Pettinger A, Hanson C, Erlichman C, Habermann TM, Reeder C, Nikcevich D, Bowen D, Conte M, Boysen J, Secreto C, Lesnick C, Tschumper R, Jelinek D, Kay NE, Ding W. Larsen JT, et al. Am J Hematol. 2017 Aug;92(8):759-763. doi: 10.1002/ajh.24762. Epub 2017 Jun 1. Am J Hematol. 2017. PMID: 28402581 Free PMC article. Clinical Trial.
18 results